search
Back to results

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Primary Purpose

Triple-negative Breast Cancer

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Apatinib
capecitabine
Sponsored by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Triple-negative Breast Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age:18~75 years;
  2. Triple-negative breast cancer (TNBC) confirmed by histology examination;
  3. patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria;
  4. received endocrine therapy for metastatic disease before first-line chemotherapy were allowed;
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  6. A life expectancy of more than 12 weeks;
  7. Baseline blood routine examination in accordance with the following criteria : ANC≥1.5×109/L,PLT≥90×109/L,Hb≥90g/L;
  8. Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases.

    the creatinine clearance rate calculated greater than 60 mL/min;

  9. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose;
  10. Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements.

Exclusion Criteria:

  1. Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy;
  2. controlled high blood pressure, systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg;
  3. urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g;
  4. abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN);
  5. Pregnant or lactating woman;
  6. Symptomatic brain parenchymal and/or pia mater metastases without treatment and control;
  7. Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer;
  8. Mental illness or other condition that affects patient compliance;
  9. serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently;
  10. Can not take or absorb oral drugs;
  11. Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial;
  12. The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative);
  13. Known or suspected to be allergic to any research drug or excipient;
  14. Any other researcher believes that it is not appropriate to participate in this test.

Sites / Locations

  • Cancer hospital, ChineseAMSRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Apatinib + Capecitabine

Capecitabine

Arm Description

Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d

capecitabine 1000mg/m2 bid d1-14, q21d

Outcomes

Primary Outcome Measures

progression-free survival
Time from randomization to disease progression or death for any cause

Secondary Outcome Measures

overall survival
Time from randomization to death for any cause
tine to progress
Time from randomization to disease progression
Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Full Information

First Posted
December 13, 2018
Last Updated
December 13, 2018
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT03775928
Brief Title
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Official Title
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 18, 2018 (Anticipated)
Primary Completion Date
December 1, 2020 (Anticipated)
Study Completion Date
October 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
Detailed Description
Triple-negative breast cancer (TNBC) has the characteristics of early onset, high malignancy, less treatment, and resistance to treatment. Advanced patients have shorter survival than other subtypes. Maintenance therapy after combination chemotherapy can prolong the disease control time in patients with advanced TNBC. How to prolong the disease control time of patients with advanced TNBC without affecting the quality of life has become the focus of current research. Anti-angiogenic drugs are currently one of the few targeted therapies that have achieved some efficacy in TNBC. Apatinib, a targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with breast cancer. The results of this study will help explore the new treatment of small molecule anti-angiogenic drugs for TNBC maintenance therapy, and provide some new ideas for improving individualized treatment options for patients with advanced TNBC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Triple-negative Breast Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Apatinib + Capecitabine
Arm Type
Experimental
Arm Description
Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
Arm Title
Capecitabine
Arm Type
Active Comparator
Arm Description
capecitabine 1000mg/m2 bid d1-14, q21d
Intervention Type
Drug
Intervention Name(s)
Apatinib
Intervention Description
apatinib 425mg qd po
Intervention Type
Drug
Intervention Name(s)
capecitabine
Intervention Description
capecitabine 1000mg/m2 bid d1-d14
Primary Outcome Measure Information:
Title
progression-free survival
Description
Time from randomization to disease progression or death for any cause
Time Frame
up to 6 months
Secondary Outcome Measure Information:
Title
overall survival
Description
Time from randomization to death for any cause
Time Frame
up to 6 months
Title
tine to progress
Description
Time from randomization to disease progression
Time Frame
up to 6 months
Title
Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame
up to 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age:18~75 years; Triple-negative breast cancer (TNBC) confirmed by histology examination; patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; received endocrine therapy for metastatic disease before first-line chemotherapy were allowed; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; A life expectancy of more than 12 weeks; Baseline blood routine examination in accordance with the following criteria : ANC≥1.5×109/L,PLT≥90×109/L,Hb≥90g/L; Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases. the creatinine clearance rate calculated greater than 60 mL/min; Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose; Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements. Exclusion Criteria: Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy; controlled high blood pressure, systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg; urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g; abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN); Pregnant or lactating woman; Symptomatic brain parenchymal and/or pia mater metastases without treatment and control; Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer; Mental illness or other condition that affects patient compliance; serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently; Can not take or absorb oral drugs; Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial; The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative); Known or suspected to be allergic to any research drug or excipient; Any other researcher believes that it is not appropriate to participate in this test.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Binghe Xu
Phone
86-87788826
Ext
861087788120
Email
xubinghe@medmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Bo Lan
Phone
86-87788114
Ext
861087788120
Email
daxiaolanbo@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Binghe Xu
Organizational Affiliation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cancer hospital, ChineseAMS
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Binghe Xu, PhD
Phone
86-10-87788826
Email
xubinghe@medmail.com
First Name & Middle Initial & Last Name & Degree
Bo Lan, PhD
Phone
86-10-87788114
Email
daxiaolanbo@163.com
First Name & Middle Initial & Last Name & Degree
Binghe Xu, PhD
First Name & Middle Initial & Last Name & Degree
Fei Ma, PhD
First Name & Middle Initial & Last Name & Degree
Bo Lan, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

We'll reach out to this number within 24 hrs